24May 2022
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro

What is the value of faster acting prandial insulin? Focus on ultra rapid lispro

Increased demand for faster-acting insulins that can quickly control PPG excursions without increasing the risk for late hypoglycemia led to the development of ultra‐rapid acting insulins, including ultra-rapid lispro (URLi). Clinical pharmacology studies consistently demonstrated an earlier onset and shorter action duration with URLi than with Lispro. This review focuses on the clinical and pharmacological evidence for URLi in the treatment of diabetes and discuss potential benefits and considerations with URLi compared with RAIs.

  • #endo-diabetology

Like

Save

Share